For example, a clinical study revealed that neoadjuvant degarelix is related to the upregulation of DHT in tumors.180 Other studies have found that the administration of GnRH agonists or antagonists can decrease lean body mass and increase fat mass.181–183 Further studies will provide critical evidence to address whether GnRH agonists or antagonists are safe for patients with cardiovascular disease. This evidence concerns the gene GNRH1 and cardiovascular disorder.